A diagnosis of adenocarcinoma of the bladder requires careful and specialized care. Because it is rare, it is essential to be treated by a multidisciplinary team, including a urologic oncologist, ...
Providing surgeons feedback and education on their performance significantly improved the quality of bladder cancer ...
Bipolar transurethral resection represents a significant evolution in the surgical management of bladder cancer, particularly for non‐muscle invasive bladder cancer (NMIBC). This technique utilises an ...
EORTC GUCG 2418 - STARBURST: Strategies for treatment adaptation following re-evaluation of the bladder after using primary neoadjuvant systemic therapies—An EORTC platform trial. This is an ASCO ...
Man patients with MIBC are ineligible for or refuse SOC cisplatin. SunRISe-4 evaluated neoadjuvant gemcitabine intravesical system (TAR-200) plus cetrelimab or cetrelimab monotherapy for pathologic ...
Richard T. Bryan, PhD, Wenyu Liu, PhD, Sarah J. Pirrie, MSc, Rashid Amir, FRCR, Jean Gallagher, Ana I. Hughes, MSc, Kieran P. Jefferson, FRCS, Allen Knight, MBA ...
The combination of Keytruda and Padcev is taking another major step toward securing its position as a leading therapy in the ...
What Is Zusduri Used For? Zusduri is used to treat a certain type of recurrent, persistent bladder cancer known as LG-IR-NMIBC. About 75% of people with bladder cancer present with non-muscle invasive ...
The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...
A combination of the antibody-drug conjugate enfortumab vedotin (Padcev) and the PD-1 inhibitor pembrolizumab (Keytruda) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback